LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.21−0.29 (-8.29%)
Close on Nov 18, 2026Market cap $100.86MP/E –Yield –
LENZ Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
LENZ Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $21.48M, up 329.5% year over year. For fiscal 2025 it was $19.09M.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.09M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.49M | +9.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.90M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.59M | – |
| Q3 FY2025 | Sep 30, 2025 | $12.50M | – |
| Q2 FY2025 | Jun 30, 2025 | $5.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
See a number that looks wrong?